StockData
Pure Bioscience, Inc. logo

Pure Bioscience, Inc. (PURE) company profile

PUREOTCMiscellaneous Chemical ProductsFiscal year ends July 31
Số liệu tài chính tới Q4 năm tài chính 2026, quý kết thúc ngày Jul 31, 2026Last filing: 10-K on Oct 29, 2026Score 1/30
$0.07−0.01 (-12.10%)

Close on Oct 19, 2026Market cap $8.67MP/E –Yield –

About Pure Bioscience

Miscellaneous Chemical Products, SIC 2890

PURE Bioscience, Inc. develops and commercializes antimicrobial products designed to address pathogen and hygienic control challenges across various industries. Its core technology platform utilizes patented silver dihydrogen citrate (SDC), an electrolytically generated stabilized ionic silver molecule. The company's primary products include PURE Hard Surface, an EPA-registered disinfectant and sanitizer for food contact surfaces, and PURE Control, an FDA-approved direct food contact processing aid for poultry and produce. Additionally, it sells multi-purpose cleaners and SILVÉRION, an SDC-based raw material ingredient used in personal care formulations. PURE Bioscience markets its offerings directly and through third-party distributors to food processing plants, food service and restaurant operations, hospitality businesses, healthcare facilities, and commercial buildings.

The company operates within a single reportable segment and conducts its business from principal executive offices in El Cajon, California. Its products are distributed domestically and marketed outside the United States, including registrations in Canada and international sales of its raw material ingredients.

Summary of the business section of Pure Bioscience's latest annual report, written by StockData.

Company profile

Company

Legal name
Pure Bioscience, Inc.
Founded
1992
Headquarters
El Cajon, CA
Address
771 Jamacha Road #512 92019
Phone
(619) 596-8600
Employees
11, Jul 31, 2026
Industry
Miscellaneous Chemical Products
Incorporated in
Delaware
Fiscal year ends
July 31
Auditor
Weinberg & Company, P.A., Los Angeles, California

Stock & identifiers

Ticker
PURE
Exchange
OTC
IPO date
Aug 8, 1996
Shares outstanding
140M, Oct 29, 2026
Public float
$2.98M, Jan 31, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
Stock splits
1-for-8 reverse, Aug 15, 2012
SEC CIK
1006028
FIGI
BBG000BVNF18
Share class FIGI
BBG001S71679
EIN
33-0530289

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Jeffrey Scott KitchellPresident, Corporate Secretary12,998

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryOption awardsTotalvs. prior year
Robert Bartlett
Chief Executive Officer
$151.90K$39.40K$191.30K-11%
Mark Elliott
Vice President Finance
$169.20K$9.40K$178.60K-8%
Tom Myers
Executive Vice President of Technology & Development
$188.00K$9.40K$197.40K-8%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Employees

Headcount reported in annual reports

“As of October 29, 2026, we have 10 full-time employees and 1 part-time employee. We believe we have successfully attracted skilled and experienced talent; however, the competition for qualified perso”

Corporate history

Events identified from SEC filings

DateEventDetails
Nov 20, 2019Auditor changeChange in certifying accountant (8-K Item 4.01)
Dec 10, 2015Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Aug 20, 2013Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Aug 20, 2013DelistingNotice of delisting from exchange (Form 25)
May 17, 2013Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Mar 8, 2013Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Dec 26, 2012Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Oct 5, 2012Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Sep 18, 2012Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Sep 14, 2012Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Aug 16, 2012Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Aug 8, 2012Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jun 26, 2012Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Mar 28, 2012Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Mar 16, 2012Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Sep 22, 2011Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Mar 17, 2011Name changeName changed from PURE BIOSCIENCE to Pure Bioscience, Inc.
Mar 31, 2008ListingRegistration of securities on an exchange (Form 8-A)
Sep 24, 2007Auditor changeChange in certifying accountant (8-K Item 4.01)
Jun 3, 2005Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Sep 2, 2003Name changeName changed from INNOVATIVE MEDICAL SERVICES to PURE BIOSCIENCE
Nov 15, 2001DeregistrationTermination of SEC registration (Form 15)
Jul 15, 1996ListingRegistration of securities on an exchange (Form 8-A)

See a number that looks wrong?